| Feb 19, 2026 | Altesa | $75.0M Series B | Jon Edwards | Atlantic Partners, Pitango Venture Capital, Sanofi |
| Dec 10, 2025 | D3 Bio | $108.0M Series B | — | IDG Capital, Matrix Partners China, Sequoia Capital, Temasek, WuXi AppTec |
| May 1, 2025 | Fore Biotherapeutics | $40.0M Series D | — | Roberto De Ponti, 3B Future Health Ventures (Helsinn Investment Fund), Hbm Partners, Novartis Venture Fund, Pontifax Venture Capital, SR One, 3B Future Health Fund, Cormorant Asset Management, Novartis, OrbiMed, Wellington Management |
| Mar 1, 2025 | Curevo | $110.0M Series B | Medicxi | BoxOne Ventures, Ali Tamaseb |
| Apr 8, 2024 | D3 Bio | $62.0M Series A | Francesco De Rubertis | Matrix Partners China, WuXi AppTec |
| Feb 13, 2024 | ProfoundBio | $112.0M Series B | Andrew Lam | Janus Henderson Investors, LifeSci Venture Partners, Josh Jin, Logos Capital, LYFE Capital, Nextech Invest, Octagon Capital, OrbiMed, Piper Heartland Healthcare Capital, RA Capital Management, Surveyor Capital, T. Rowe Price Associates |
| Sep 1, 2022 | Rivus Pharmaceuticals | $130.0M Series B | Derek DiRocco | Qiming Venture Partners, RA Capital, Bain Capital Life Sciences, BB Biotech, Longitude Capital, RxCapital |
| Jun 1, 2022 | MiroBio | $97.0M Series B | Nick Williams | Advent Life Sciences, Atlas Venture, Draper Associates, F-Prime Capital Partners, Global Ventures, Maverick Capital, Novartis Venture Fund, Questa Capital, SR One, Wellington Partners, Curtis Chambers, Advent Life Sciences, Monograph Capital, Erez Chimovits, Oxford Science Enterprises, Samsara BioCapital |
| Sep 8, 2021 | Xenikos | $47.5M Other Equity | Craig A. Collard | Oost NL, RA Capital Management, Sanquinnovate |
| Aug 10, 2021 | Sydnexis | $45.0M Series B | Tyler Stowater, SC Master Fund, Jeffry Weinhuff | Gregory Grunberg, M.D., Zach Scheiner |
| Aug 1, 2021 | Versanis Bio | $70.0M Series A | Atlas Venture, Nick Williams | Access Biotechnology, Aditum Bio, Canaan Partners, RA Capital |
| Jul 22, 2021 | Rivus Pharmaceuticals | $35.0M Series A | Longitude Capital, Medicxi | RxCapital |
| Jun 10, 2021 | Kurome Therapeutics | $15.0M Series A | Daniel Heller, Aaron Kantoff | CincyTech |
| Mar 22, 2021 | Aura Biosciences | $80.0M Other Equity | Karan Takhar, Surveyor Capital | Adage Capital Management, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfond Ventures, Rock Springs Capital, Velosity Capital, Joel Jean Mairet |
| Nov 1, 2020 | SynOx Therapeutics | $44.0M Series A | HealthCap, Medicxi | Oscar Slotboom, Rob de Ree, Forbion |
| Oct 7, 2020 | Janpix | $10.0M Series B | Sandy Zweifach | — |
| Sep 1, 2020 | Palladio Biosciences | $20.0M Series B | Srinivas Akkaraju | Red Tree Venture Capital, Francesco De Rubertis, Osage University Partners, Roche |
| Jun 1, 2020 | Checkmate Pharmaceuticals | $85.0M Series C | Oren K. Isacoff, M.D., Nilesh Kumar | Andreessen Horowitz, Cofounders Capital, F-Prime Capital Partners, Locus Ventures, Carol Gallagher, NextView Ventures, Omega Funds, Runway Growth Capital, SV Health Investors, The Column Group, The House Fund, venBio, Vida Ventures, XX, Y Combinator, James Park, Jason Wang, Jon Brelig, Manik Gupta, Ralph Gootee, BrightEdge, Decheng Capital, F-Prime Capital, Sectoral Asset Management, Sofinnova Ventures |
| Mar 1, 2020 | Vaxcyte | $110.0M Series D | Agustin Mohedas, Derek DiRocco | RA Capital, Abingworth, CTI Life Sciences Fund, Foresite Capital, Frazier Healthcare Partners, Longitude Capital, Pivotal bioVenture Partners, Roche, TPG Growth |
| Jan 9, 2020 | Alderaan Biotechnology | $20.6M Series A | Matthieu Coutet, Michele Ollier | — |
| Sep 18, 2019 | Divide and Conquer | $12.4M Series A | David Grainger | — |
| Apr 2, 2019 | Aura Biosciences | $40.0M Series D | Giovanni Mariggi | Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfond Ventures, Ysios Capital |
| Jun 7, 2018 | Vaxcyte | $85.0M Series C | Heath Lukatch | Abingworth, CTI Life Sciences Fund, Foresite Capital, Frazier Healthcare Partners, Longitude Capital, Francesco De Rubertis, Pivotal bioVenture Partners, Roche |
| May 1, 2018 | Xenikos | $30.0M Series B | — | Avalon Ventures, OrbiMed, RA Capital, Red Tree Venture Capital, RA Capital Management |
| Apr 1, 2018 | Synthorx | $63.0M Series C | OrbiMed | Morgenthaler Ventures, RA Capital, Samsara BioCapital, SR One, Avalon Ventures, Correlation Ventures, Osage University Partners, RA Capital Management |
